The oversubscribed financing was led by Ahren Innovation Capital and will support preclinical validation and platform development.
"Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team."
The financing round was led by Ahren Innovation Capital and will support the expansion of the company's in-house target discovery programme.
"OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected."
Northern Gritstone led the over-subscribed seed round with participation from Empirical Ventures, Praetura Ventures, and private backers.
"Northern Gritstone is delighted to support Exciting Instruments’ internationally renowned team from the University of Sheffield. Their technology will open up a broad range of health-related research and discovery and will also support job creation in Sheffield’s thriving tech cluster."
Northern Gritstone led the seed extension round, which included participation from ACF Investors, Empirical Ventures, Deeptech Labs, and Hamamatsu Ventures.
"The progress made by the Silveray team since our initial investment in 2023 has been phenomenal. Dan Cathie and his team have the enviable combination of innovation and entrepreneurialism having developed a novel digital x-ray solution with numerous applications which are already disrupting the analogue x-ray market. We are delighted to continue our support of Silveray as it builds its commercial traction, helping the team on its path to success."
The capital injection will accelerate the silicon roadmap for minimally invasive neural implant applications.
"Our semiconductor-based approach is fundamentally reshaping what neural implants can achieve. By offering a customisable, compact solution that integrates seamlessly into medical devices, we’re empowering a new era of neural interfaces that are not only more powerful but also less invasive. This marks a transformative shift in neurological care."
Soulmates Ventures and Deeptech Seed Fund co-led the seed round, which includes £500k from Innovate UK.
"I couldn't be more excited and proud about this next stage in our growth. It is a landmark opportunity, a once in a lifetime moment, to build a transformative product."
The financing round will help the medical technology company advance its epilepsy diagnosis software towards US and Middle Eastern markets.
"We are delighted to have invested in Neuronostics, whose software as a medical device could revolutionise how neurological conditions are diagnosed and treated."
